| Roche–Oxford BioTherapeutics: antibody cancer drugs, 202503– collab strategic $36m upfront + >$1b milestones using OGAP Verify for Ab cancer drugs |
2025-03-19 |
| BioClec–Sofinnova: investment, 202503 launch emerging from Sofinnova Biovelocita II acclerator programme |
2025-03-18 |
| Araris Biotech–ICR: public relations, 202503 service existent by ICR Healthcare Europe |
2025-03-17 |
| Latigo Biotherapeutics–SEVERAL: investment, 202503 financing round Series B $150m led by Blue Owl Capital |
2025-03-17 |
| C2N Diagnostics–Samsung: investment, 202503 investment $10m from Samsung C&T + Samsung Biologics + Samsung Bioepis + Samsung Venture Investment |
2025-03-13 |
| Haya Therapeutics–Linnden Communications: public relations, 202503 service existent by Linnden Communciations |
2025-03-13 |
| Insilico Medicine–SEVERAL: investment, 202503 financing round Series E $110m led by Value Partners Group |
2025-03-13 |
| Insilico Medicine–Value Partners Group: investment, 202503 financing round Series E totalling $110m incl lead investor Value Partners Group |
2025-03-13 |
| Deep 6 AI–Tempus: investment, 202503 acquisition of Deep 6 AI by Tempus AI Inc |
2025-03-11 |
| 2seventy Bio–BMS: investment, 202503– acquisition cash tender offer $286m (= $102m net of cash) by BMS |
2025-03-10 |
| Checkpoint Therapeutics–Sun Pharmaceutical: investment, 202503– acquisition $355m upfront cash + $60.1m CVRs |
2025-03-10 |
| Chimerix–Jazz Pharmaceuticals: investment, 202503– acquisition cash tender offer $935m at $8.55/share by Jazz Pharmaceuticals |
2025-03-05 |
| Epoch Biodesign–SEVERAL: investment, 202503 financing round Series A $17.3m led by Extantia Capital |
2025-03-05 |
| OmicScouts–Momentum Biotechnologies: investment, 202503 acquisition of OmicScouts GmbH by Momentum Biotechnologies |
2025-03-05 |
| Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF |
2025-03-05 |
| Xund Solutions–MassMutual: investment, 202503 financing round pre-Series A totalling €6m incl existing + co-investor MassMutual Ventures |
2025-03-05 |
| Xund Solutions–SEVERAL: investment, 202503 financing round pre-Series A €6m led by Lead Ventures |
2025-03-05 |
| Callio Therapeutics–Hummingbird Bioscience: antibody-drug conjugates, 202503– license excl ww ADC technology in oncology + related IP + pipeline |
2025-03-03 |
| Callio Therapeutics–SEVERAL: investment, 202503 financing round Series A $187m led by founding investor Frazier Life Sciences |
2025-03-03 |
| Enveda–Sanofi: investment, 202502 financing round Series C extension $20m? from Sanofi |
2025-02-26 |
| Solventum–Thermo Fisher: investment, 202502– acquisition $4.1b in cash of purification + filtration business by Thermo Fisher |
2025-02-25 |
| Bluebird Bio–Carlyle: investment, 202502– acquisition of Bluebird Bio by funds managed by Carlyle + SK Capital Partners + delisting |
2025-02-21 |
| Bluebird Bio–SK Capital: investment, 202502– acquisition of Bluebird Bio by funds managed by Carlyle + SK Capital Partners + delisting |
2025-02-21 |
| EG427–SEVERAL: investment, 202502 financing round Series B €27m co-led by Andera Partners + Bpifrance InnoBio funds |
2025-02-20 |
| FibroGen–AstraZeneca: investment, 202502 acquisition $160m (incl acquired net cash of $75m) of FibroGen China by AZ incl rights to roxadustat in China |
2025-02-20 |
| Atai Life Sciences–Angermayer Group: investment, 202502 public offering totalling $63.25m incl $22.75m from Apeiron raising share from 19.9% to 22.3% |
2025-02-19 |
| Atai Life Sciences–SEVERAL: investment, 202502 public offering $55m+$8.25m with 26.19m+3.93m common shares at $2.1/share |
2025-02-19 |
| Atrandi Biosciences–Grids Capital: investment, 202502 financing round Series A totalling $25m incl co-investor Grids Capital |
2025-02-19 |
| Atrandi Biosciences–KKH Advisors: public relations, 202502 service existent by KKH Advisors |
2025-02-19 |
| Atrandi Biosciences–Lux Capital: investment, 202502 financing round Series A totalling $25m incl lead investor Lux Capital |
2025-02-19 |
| Atrandi Biosciences–SEVERAL: investment, 202502 financing round Series A $25m led by Lux Capital |
2025-02-19 |
| Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share |
2025-02-18 |
| Bambusa Therapeutics–SEVERAL: investment, 202502 financing round Series A $90m led by new investor RA Capital Management |
2025-02-14 |
| Bürkert Fluidic Control Systems–Green Elephant Biotech: cell culture technology, 202502 strategic partnership incl strategic investment by Bürkert |
2025-02-13 |
| Green Elephant Biotech–Bürkert Fluidic Control Systems: investment, 202502 strategic investment by Bürkert as part of strategic partnership |
2025-02-13 |
| Latent Labs–SEVERAL: investment, 202502 financing round Series A $40m co-led by Radical Ventures + Sofinnova Partners |
2025-02-13 |
| Latent Labs–SEVERAL: investment, <202502 financing round pre-Series A? $10m incl 8VC + Kindred Capital + Pillar VC |
2025-02-13 |
| Oculis–SEVERAL: investment, 202502 underwritten offering $100m with 5m ordinary shares at $20/share |
2025-02-13 |
| Pfizer–Som.X: public relations, 202502 service existent? Pfizer listed as client at web site |
2025-02-13 |
| Stilla Technologies–Bio-Rad: investment, 202502– acquisition 100% of Stilla Technologies by Bio-Rad SIGNED |
2025-02-13 |
| Anthos Therapeutics–Novartis: investment, 2020502– acquisition $925m upfront + $2.15b milestones by Novartis from majority owner Blackstone LS et al |
2025-02-11 |
| Stellaromics–Catalyst4: investment, 202502 financing round Series B totalling $80m incl lead investor Catalyst4 |
2025-02-11 |
| Stellaromics–Oak Street Communications: public relations, 202502 service existent Oak Street is media contact for Stellaromics |
2025-02-11 |
| Stellaromics–SEVERAL: investment, 202502 financing round Series B $80m led by Catalyst4 |
2025-02-11 |
| Stellaromics–Stanford Univ: investment, 202502 financing round Series B totalling $80m incl co-investor Stanford University Ventures |
2025-02-11 |
| Sionna Therapeutics–SEVERAL: investment, 202502 IPO $219.2m with 10.6m+1.6m shares common stock at $18/share at Nasdaq Global Market |
2025-02-10 |
| Mitsubishi Chemical–Bain Capital: investment, 202502– carve-out acquisition JPY510b ($3.3b) of Mitsubishi Tanabe Pharma Corp by Bain Capital |
2025-02-07 |
| Avelios Medical–SEVERAL: investment, 202502 financing round Series A €30m led by Sequoia Capital |
2025-02-06 |
| Avalyn Pharma–Qureight: drug development services, 202502– collab using Qureight imaging technology in multiple Avalyn clinical studies |
2025-02-05 |
| Akribion–Bruker: investment, 202502 seed financing round totalling €8m incl co-investor Bruker Invest |
2025-02-04 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Evaxion Biotech–SEVERAL: investment, 202501 public offering $10.8m with 4m ADSs each with 2 attached warrants at $2.71/ADS+warrants |
2025-01-31 |
| Delfina–Artis Ventures: investment, 202501 financing round Series A totalling $17m incl new + co-investor Artis Ventures |
2025-01-28 |
| Delfina–Boutique Ventures: investment, 202501 financing round Series A totalling $17m incl existing + co-investor Boutique Ventures |
2025-01-28 |
| Delfina–Bread and Butter Ventures: investment, 202501 financing round Series A totalling $17m incl existing + co-investor Bread and Butter Ventures |
2025-01-28 |
| Delfina–Mayo Clinic: investment, 202501 financing round Series A totalling $17m incl new + co-investor Mayo Clinic |
2025-01-28 |
| Delfina–Metrodora Ventures: investment, 202501 financing round Series A totalling $17m incl existing + co-investor Metrodora Ventures |
2025-01-28 |
| Delfina–SemperVirens: investment, 202501 financing round Series A totalling $17m incl existing + co-investor SemperVirens |
2025-01-28 |
| Delfina–SEVERAL: investment, 202501 financing round Series A $17m led by US Venture Partners |
2025-01-28 |
| Delfina–Story Ventures: investment, 202501 financing round Series A totalling $17m incl existing + co-investor Story Ventures |
2025-01-28 |
| Delfina–Tokio Marine Future Fund: investment, 202501 financing round Series A totalling $17m incl new + co-investor Tokio Marine Future Fund |
2025-01-28 |
| Delfina–US Venture Partners: investment, 202501 financing round Series A totalling $17m incl new + lead investor USVP |
2025-01-28 |
| Arctic Therapeutics–SEVERAL: investment, 202501 financing round Series A €26.5m |
2025-01-22 |
| Zwisler Laboratorium–Cormica: investment, 202501 acquisition of Zwisler Laboratorium GmbH by Cormica |
2025-01-20 |
| Bureau Veritas–SGS: investment, 202501– confirmed merger discussion |
2025-01-15 |
| Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation |
2025-01-15 |
| Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital |
2025-01-15 |
| Bioptimus–New York Life: investment, 202501 financing round totalling $41m incl co-investor Andera Partners |
2025-01-14 |
| Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation |
2025-01-14 |
| Umoja Biopharma–SEVERAL: investment, 202501 financing round Series C $100m co-led by Double Point Ventures + DCVC Bio |
2025-01-14 |
| Ariceum Therapeutics–ITM: radiopharmaceuticals, 202501– supply €na of n.c.a.Ac-225 for Ariceum radiopharma candidates by Actineer |
2025-01-13 |
| Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939 |
2025-01-13 |
| IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed |
2025-01-13 |
| Intra-Cellular Therapies–JnJ: investment, 2020501– acquisition 100% for $14.6b in cash at $132/share by JnJ |
2025-01-13 |
| Normunity–Patient Square Capital: investment, 202501 financing round Series B totalling $75m incl new + co-lead investor Enavate Sciences |
2025-01-13 |
| Normunity–Samsara BioCapital: investment, 202501 financing round Series B totalling $75m incl new + co-lead investor Samsara BioCapital |
2025-01-13 |
| Normunity–Sanofi: investment, 202501 financing round Series B totalling $75m incl existing + co-investor Sanofi Ventures |
2025-01-13 |
| Normunity–SEVERAL: investment, 202501 financing round Series B $75m co-led by Samsara BioCapital + Enavate Sciences |
2025-01-13 |
| Scorpion Therapeutics–Lilly: investment, 202501– acquisition up to $2.5b in cash with spin-out of non-PI3Ka assets in NewCo with minority for Lilly |
2025-01-13 |
| Akoya Biosciences–Quanterix: investment, 202501– merger acquisition with former Quanterix shareholders owning 70% ANNOUNCED |
2025-01-10 |
| Windward Bio–Blue Owl Capital: investment, 202501 financing round Series A totalling $200m incl co-lead investor Blue Owl Healthcare Opportunities |
2025-01-10 |
| Windward Bio–Kelun Pharmaceutical: TSLP antibody, 202501– license ww excl China + smaller Asian markets to WIN378 from Kelun-Biotech + Harbour Biomed |
2025-01-10 |
| Windward Bio–Omega Funds: investment, 202501 financing round Series A totalling $200m incl co-investor Omega Funds |
2025-01-10 |
| Windward Bio–OrbiMed: investment, 202501 financing round Series A totalling $200m incl co-lead investor OrbiMed |
2025-01-10 |
| Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners |
2025-01-10 |
| Windward Bio–RTW Investments: investment, 202501 financing round Series A totalling $200m incl co-investor RTW Investments |
2025-01-10 |
| Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
| Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One |
2025-01-10 |
| Coave Therapeutics–Invus Group: investment, 202501 financing round Series A totalling €32m incl new + co-investor Invus |
2025-01-09 |
| Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio |
2025-01-09 |
| Numab–Cormorant Asset Management: investment, 202501 financing round Series C extension totalling CHF50m incl existing + co-lead investor Cormorant AM |
2025-01-09 |
| Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m |
2025-01-09 |
| Alesta Therapeutics–Frazier: investment, 202501 financing round Series A totalling €65m incl co-lead investor Frazier Life Sciences |
2025-01-08 |
| Alesta Therapeutics–Kendall Investor Relations: public relations, 202501 supply service existent by Kendall IR |
2025-01-08 |
| Alesta Therapeutics–RTW Investments: investment, 202501 financing round Series A totalling €65m incl co-investor RTW Investments |
2025-01-08 |
| Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures |
2025-01-08 |
| Senseera–I-Next Capital: investment, 202501 seed financing round totalling $7.1m incl co-investor I-Next Capital |
2025-01-07 |
| Senseera–Lightspeed Venture Partners: investment, 202501 seed financing round totalling $7.1m incl lead investor Lightspeed VP |
2025-01-07 |
| Senseera–Lowy Medical Research Institute: investment, 202501 seed financing round totalling $7.1m incl co-investor Lowy Medical Research Institute |
2025-01-07 |
| Senseera–SEVERAL: investment, 202501 seed financing round $7.1m led by Lightspeed Venture Partners |
2025-01-07 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
